October 26, 2026
Advocates Push to Expand Lung Cancer Screening Beyond Smoking
NPR
Research News
Explore our curated selection of the latest breakthroughs in lung cancer research.
October 26, 2026
NPR
October 25, 2026
A new study offers hope for people with EGFR lung cancer whose treatment stopped working. Published in the New England Journal of Medicine, it found that osimertinib and savolitinib together beat chemotherapy.
The New England Journal of Medicine
October 24, 2026
Tarlatamab small cell lung cancer research just took a major step forward. A new study in the New England Journal of Medicine found that adding tarlatamab to standard maintenance treatment helped patients live much longer.
The New England Journal of Medicine
October 6, 2026
JAMA Network
September 22, 2026
Cancer researchers are increasingly studying the whole body, not just the tumor, and listening more closely to patients’ own experiences.
CURE
September 19, 2026
A new targeted therapy produced a 94% response rate in ROS1-positive lung cancer, with strong results even against brain metastases.
CURE
September 17, 2026
TIME
September 1, 2026
The CDC’s 2026 report finds falling lung cancer death rates are the biggest reason U.S. cancer mortality keeps declining after more than 20 years.
CDC Newsroom
August 11, 2026
A new study found blood changes linked to air pollution exposure show up years before a lung cancer diagnosis.
Nature Communications
August 4, 2026
Not long ago, lung cancer had almost no organized patient advocacy and nowhere near the visibility that breast cancer or pediatric cancer communities had built. A new article in the Journal of Thoracic Oncology, co-written by four advocates and researchers — including LCFA’s own Jill Feldman — traces how that changed over the past two decades, and what’s still unfinished.
Journal of Thoracic Oncology
July 31, 2026
A large new study finds that Veterans with lung cancer who get care through the Veterans Health Administration (VA) are surviving longer than people treated at other U.S. hospitals.
Researchers looked at more than 1.4 million people diagnosed with non-small cell lung cancer, the most common type, between 2007 and 2019. They compared about 79,000 Veterans treated at the VA with about 1.38 million patients treated at community hospitals across the country.
In 2007, both groups had the same chance of being alive three years after diagnosis: 24%. By 2019, that number had climbed to 51% for Veterans treated at the VA, compared with 41% for patients treated elsewhere. The VA also did better than academic and research hospitals, which reached 46%.
The difference showed up at every stage of the disease. That stands out because the Veterans in the study were older and had more health problems than the other patients.
What might explain it? In an editorial about the study, Dr. Drew Moghanaki, a member of LCFA’s Scientific Advisory Board, and his co-authors point to how VA care is organized. National programs guide surgery, radiation and cancer medicine. Most VA medical centers partner with academic medical centers. Teams of specialists review cases together. And Veterans can get help with housing, money and transportation, the kinds of problems that can interrupt treatment.
The study did not prove why the VA did better, and it doesn’t mean every VA hospital does better than every other hospital. But it shows what’s possible when care is built around the whole person.
What this means for you: if you are a Veteran, ask your VA care team whether lung cancer screening is right for you. Finding lung cancer early gives you more treatment options.
Journal of the National Cancer Institute
July 23, 2026
The FDA approved a new targeted drug for adults with advanced non-small cell lung cancer that has a gene change called a ROS1 fusion, and whose cancer kept growing after treatment with an earlier ROS1 drug.
Oncology News Central
Learn more about:
LCFA prioritizes providing reliable information about new diagnostics, treatments, and prevention strategies, including exciting FDA-approved personalized therapies based on individual tumor biomarkers. Human-reviewed, AI-created content is used to create some of the summaries for the articles listed.